Fever, Cough, Painkillers and Vitamin Supplements Among 16 Medicines Declared Substandard in Rajasthan

Jaipur:
In a major public health alert, the Rajasthan Drug Controller Department has ordered the immediate withdrawal of 16 medicines from the market after they failed to meet prescribed quality standards during laboratory testing. The samples of these medicines were collected between January 1 and January 15, 2026, and were found to be substandard.

According to officials, the quality tests revealed that several of these medicines contained insufficient active pharmaceutical ingredients and did not dissolve properly in the body. Such deficiencies can significantly reduce the effectiveness of treatment and may pose serious health risks to patients.

Health Department Issues Advisory

Following the findings, the Rajasthan Health Department has appealed to the general public to immediately stop consuming these medicines. People have been advised to check the batch numbers of medicines available with them and consult doctors for alternative prescriptions if required.

The Drug Controller has also issued instructions for strict action against manufacturers and distributors found violating drug quality norms.

Commonly Used Medicines Affected

The list of failed medicines includes several commonly used drugs, raising concerns among patients and healthcare providers. Among the affected medicines are:

• Paracetamol used for fever and pain relief
• Cough medicines containing Ambroxol, Terbutaline and Guaifenesin
• Calcium and Vitamin D3 supplements
• Certain antibiotics
• Some medicines used for blood pressure control

Officials warned that the use of such substandard medicines could delay recovery and worsen health conditions, especially in vulnerable patients.

Immediate Market Recall Ordered

The department has directed all medical stores and distributors to immediately remove the affected batches from sale. Continuous monitoring and inspections are being carried out to ensure compliance across the state.

The Drug Controller Department reiterated its commitment to ensuring patient safety and drug quality, stating that regular inspections and laboratory testing will continue, and any compromise with public health will be dealt with strictly under the law.

This action serves as a strong reminder for consumers to remain vigilant and for pharmaceutical companies to adhere strictly to quality and safety standards.